benzimidazoles

Summary

Summary: Compounds with a BENZENE fused to IMIDAZOLES.

Top Publications

  1. doi Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
    S Yusuf
    Lancet 372:1174-83. 2008
  2. doi Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
  3. ncbi Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase
    Simon A Hawley
    Division of Molecular Physiology University of Dundee, Dundee, Scotland, United Kingdom
    Cell Metab 2:9-19. 2005
  4. ncbi The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases
    Rebecca L Hurley
    Departments of Medicine and Biochemistry, Dartmouth Medical School and the Department of Biological Sciences, Dartmouth College, Hanover, NH 03755, USA
    J Biol Chem 280:29060-6. 2005
  5. doi Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials
    Ken Uchino
    Cerebrovascular Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, Mail Code S80, Cleveland, OH 44195, USA
    Arch Intern Med 172:397-402. 2012
  6. ncbi Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Joanne van Ryn
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Thromb Haemost 103:1116-27. 2010
  7. doi Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
    John W Eikelboom
    Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
    Circulation 123:2363-72. 2011
  8. ncbi Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Lancet 362:759-66. 2003
  9. doi Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation
    James V Freeman
    Stanford University School of Medicine, California, USA
    Ann Intern Med 154:1-11. 2011
  10. ncbi Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells
    Angela Woods
    Cellular Stress Group, MRC Clinical Sciences Centre, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom
    Cell Metab 2:21-33. 2005

Research Grants

  1. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2006
  2. Oxidative Stress in Oral Streptococci
    Robert E Marquis; Fiscal Year: 2010
  3. ANTIFUNGAL RESPONSE--MDR INDUCTION
    Thomas Edlind; Fiscal Year: 2001
  4. ANTIFUNGAL RESPONSE--MDR INDUCTION
    Thomas Edlind; Fiscal Year: 1999
  5. ANTIFUNGAL RESPONSE--MDR INDUCTION
    Thomas Edlind; Fiscal Year: 2000
  6. ANTIFUNGAL RESPONSE--MDR INDUCTION
    Thomas Edlind; Fiscal Year: 2002
  7. DISCRIMINATION BETWEEN VIABLE & DEAD ENCEPHALITOZOON CUNICULI (MICROSPORIDIA)
    Linda Green; Fiscal Year: 2000
  8. DICATIONIC DRUGS--TREATMENT FOR AIDS-RELATED INFECTIONS
    Richard Tidwell; Fiscal Year: 1999
  9. Novel Antimicrobials Targeting Cell Division
    Iwao Ojima; Fiscal Year: 2010
  10. Novel Antimicrobials Targeting Cell Division
    Iwao Ojima; Fiscal Year: 2011

Detail Information

Publications329 found, 100 shown here

  1. doi Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
    S Yusuf
    Lancet 372:1174-83. 2008
    ..We therefore assessed whether the angiotensin-receptor blocker telmisartan would be effective in patients intolerant to ACE inhibitors with cardiovascular disease or diabetes with end-organ damage...
  2. doi Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
    ..Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor...
  3. ncbi Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase
    Simon A Hawley
    Division of Molecular Physiology University of Dundee, Dundee, Scotland, United Kingdom
    Cell Metab 2:9-19. 2005
    ..Our results suggest a potential Ca(2+)-dependent neuroprotective pathway involving phosphorylation and activation of AMPK by CaMKKbeta...
  4. ncbi The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases
    Rebecca L Hurley
    Departments of Medicine and Biochemistry, Dartmouth Medical School and the Department of Biological Sciences, Dartmouth College, Hanover, NH 03755, USA
    J Biol Chem 280:29060-6. 2005
    ..These data indicate that the CaMKKs function in intact cells as AMPKKs, predicting wider roles for these kinases in regulating AMPK activity in vivo...
  5. doi Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials
    Ken Uchino
    Cerebrovascular Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, Mail Code S80, Cleveland, OH 44195, USA
    Arch Intern Med 172:397-402. 2012
    ..We systematically evaluated the risk of MI or acute coronary syndrome (ACS) with the use of dabigatran...
  6. ncbi Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Joanne van Ryn
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Thromb Haemost 103:1116-27. 2010
    ....
  7. doi Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
    John W Eikelboom
    Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
    Circulation 123:2363-72. 2011
    ..The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial...
  8. ncbi Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Lancet 362:759-66. 2003
    ..Patients with chronic heart failure (CHF) are at high risk of cardiovascular death and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and morbidity...
  9. doi Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation
    James V Freeman
    Stanford University School of Medicine, California, USA
    Ann Intern Med 154:1-11. 2011
    ..Dabigatran is a fixed-dose, oral direct thrombin inhibitor with similar or reduced rates of ischemic stroke and intracranial hemorrhage in patients with AF compared with those of warfarin...
  10. ncbi Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells
    Angela Woods
    Cellular Stress Group, MRC Clinical Sciences Centre, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom
    Cell Metab 2:21-33. 2005
    ..These results demonstrate that AMPK is regulated by at least two upstream kinases and suggest that AMPK may play a role in Ca(2+)-mediated signal transduction pathways...
  11. doi Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, ON, Canada
    N Engl J Med 361:2342-52. 2009
    ..The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism...
  12. ncbi Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    Salim Yusuf
    McMaster Clinic, Room 252, Hamilton General Hospital, 237 Barton Street East, ON, L8L 2X2, Hamilton, Canada
    Lancet 362:777-81. 2003
    ..We investigated the effect of addition of an angiotensin-receptor blocker to current treatments...
  13. doi Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
    Lars Wallentin
    Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
    Lancet 376:975-83. 2010
    ..We aimed to investigate the primary and secondary outcomes of the RE-LY trial in relation to each centre's mean TTR (cTTR) in the warfarin population...
  14. doi Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring
    Domenic Sica
    Section of Clinical Pharmacology and Hypertension, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 13:467-72. 2011
    ..These findings suggest that AZL-M could provide higher rates of hypertension control compared with other ARBs in the class...
  15. ncbi AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical
    Barry R Davies
    Cancer and Infection Research Area, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
    Mol Cancer Ther 6:2209-19. 2007
    ..Moreover, enhanced antitumor efficacy can be obtained by combining AZD6244 with the cytotoxic drugs irinotecan or docetaxel...
  16. doi Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation
    Shimoli V Shah
    Department of Medicine, Washington University School of Medicine, Campus Box 8005, 660 S Euclid Ave, St Louis, MO 63110, USA
    Circulation 123:2562-70. 2011
    ..Recent studies have investigated alternatives to warfarin for stroke prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost-effective is unknown...
  17. ncbi Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 47:285-95. 2008
    ....
  18. doi Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension
    William B White
    Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030 3940, USA
    Hypertension 57:413-20. 2011
    ..Azilsartan medoxomil could provide higher rates of hypertension control within the ARB class...
  19. doi Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion
    Rangadham Nagarakanti
    Louisiana State University School of Medicine, New Orleans, LA, USA
    Circulation 123:131-6. 2011
    ..The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared dabigatran 110 mg BID (D110) and 150 mg BID (D150) with warfarin for stroke prevention in 18 113 patients with nonvalvular atrial fibrillation...
  20. doi Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial
    Stefan H Hohnloser
    Division of Clinical Electrophysiology, J W Goethe University Hospital, Theodor Stern Kai 7, Frankfurt, Germany
    Circulation 125:669-76. 2012
    ..There is a modest risk of myocardial infarction (MI) and myocardial ischemic events in patients with atrial fibrillation...
  21. ncbi Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials
    R J Friedman
    Medical University of South Carolina and Charleston Orthopedic Associates, Charleston, South Carolina 29414, USA
    Thromb Res 126:175-82. 2010
    ..Three randomized, double-blind trials compared dabigatran, an oral direct thrombin inhibitor, with enoxaparin for the primary prevention of venous thromboembolism (VTE) in patients undergoing elective total hip and knee arthroplasty...
  22. ncbi Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
    Bengt I Eriksson
    Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Lancet 370:949-56. 2007
    ..After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis...
  23. ncbi ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
    Cherrie K Donawho
    Abbott Laboratories, Abbott Park, Illinois 60064 6074, USA
    Clin Cancer Res 13:2728-37. 2007
    ..To evaluate the preclinical pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888...
  24. doi Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am Heart J 157:805-10, 810.e1-2. 2009
    ..The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial. Results are expected in 2009...
  25. doi Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
    Jeffrey S Ginsberg
    McMaster University Medical Centre, Ontario, Canada
    J Arthroplasty 24:1-9. 2009
    ..Dabigatran, effective compared to once-daily enoxaparin, showed inferior efficacy to the twice-daily North American enoxaparin regimen, probably because of the latter's more intense and prolonged dosing...
  26. pmc Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
    Jonathan R Dry
    Cancer Bioscience, DECS, and Clinical Biomarker Group, AstraZeneca R and D, Alderley Park, Macclesfield, United Kingdom
    Cancer Res 70:2264-73. 2010
    ..These signatures offer useful tools for the study of MEK biology and clinical application of MEK inhibitors, and the novel approaches taken may benefit other targeted therapies...
  27. doi Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
    ..We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes...
  28. pmc Telmisartan to prevent recurrent stroke and cardiovascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University, Hamilton, ON, Canada
    N Engl J Med 359:1225-37. 2008
    ..We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke...
  29. pmc The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
    Br J Clin Pharmacol 64:292-303. 2007
    ..Two double-blind, randomized trials were undertaken to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and tolerability of orally administered dabigatran etexilate in healthy male subjects...
  30. ncbi The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
    Stefan Blech
    Boehringer Ingelheim Pharma GmbH and Co KG, Department of Drug Metabolism and Pharmacokinetics, Biberach, Germany
    Drug Metab Dispos 36:386-99. 2008
    ..o. administration of dabigatran etexilate and that the potential for clinically relevant interactions between dabigatran and drugs metabolized by cytochrome P450 is low...
  31. ncbi Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice
    Jun Iwanami
    Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
    J Hypertens 28:1730-7. 2010
    ..Telmisartan is a unique AT1 receptor blocker with a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonistic action. Activation of PPAR-gamma could prevent inflammation and brain damage...
  32. pmc A distinct "side population" of cells with high drug efflux capacity in human tumor cells
    C Hirschmann-Jax
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, and DeBakey Department of Surgery, One Baylor Plaza, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 101:14228-33. 2004
    ....
  33. pmc Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
    Shivaani Kummar
    Center for Cancer Research and the Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Clin Oncol 27:2705-11. 2009
    ..It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies...
  34. doi Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter
    John A Cairns
    University of British Columbia, Vancouver, British Columbia, Canada
    Can J Cardiol 27:74-90. 2011
    ..Alternatives to antithrombotic therapies are briefly discussed...
  35. doi In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies
    Mami Ojima
    Pharmacology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, Osaka, Japan
    J Pharmacol Exp Ther 336:801-8. 2011
    ..Its tight receptor binding might be expected to produce potent and long-lasting antihypertensive effects in preclinical and clinical settings...
  36. ncbi Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
    Hans Christoph Diener
    Department of Neurology, University Hospital Essen, Essen, Germany
    Lancet Neurol 9:1157-63. 2010
    ..We aimed to assess the effects of dabigatran compared with warfarin in the subgroup of patients with previous stroke or transient ischaemic attack...
  37. doi Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Clin Pharmacokinet 49:259-68. 2010
    ..A decrease in the dose and/or an increase in the administration interval in these patients may be appropriate. In patients with ESRD, dabigatran can be partly removed from the plasma by haemodialysis...
  38. doi Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective
    S V Sorensen
    United BioSource Corporation, Bethesda, Maryland, USA
    Thromb Haemost 105:908-19. 2011
    ..This study demonstrates that dabigatran etexilate is a highly cost-effective alternative to current care for the prevention of stroke and systemic embolism among Canadian AF patients...
  39. doi Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial
    Bengt I Eriksson
    University of Gothenburg, Department of Orthopaedics, Sahlgrenska University Hospital, Molndal, Sweden
    Thromb Haemost 105:721-9. 2011
    ..The risk of bleeding and safety profiles were similar...
  40. doi The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure
    George L Bakris
    Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 13:81-8. 2011
    ..0 to -0.1; P=.038), while AZL-M 40 mg was noninferior to OLM-M 40 mg. The side effect profiles of both ARBs were similar to placebo. AZL-M is well tolerated and more efficacious at its maximal dose than the highest dose of OLM-M...
  41. ncbi Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
    Tammie C Yeh
    Array BioPharma, Inc, Boulder, Colorado 80301, USA
    Clin Cancer Res 13:1576-83. 2007
    ..We have developed a highly potent and selective inhibitor of MEK1/2. The purpose of these studies has been to show the biological efficacy of ARRY-142886 (AZD6244) in enzymatic, cellular, and animal models...
  42. doi Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells
    Y N Vashisht Gopal
    Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 70:8736-47. 2010
    ....
  43. ncbi Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am J Cardiol 100:1419-26. 2007
    ..The 2 highest doses of dabigatran suppress D-dimer concentrations. Serious liver toxicity was not seen. The significance of the increase of DTB2 concentrations in dabigatran-treated patients needs resolution...
  44. ncbi Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma
    Hung Huynh
    Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre of Singapore, Singapore 169610, Singapore
    Mol Cancer Ther 6:138-46. 2007
    ..Targeted inhibition of the MEK-ERK pathway with AZD6244 may represent an alternative approach for the treatment of this disease...
  45. ncbi STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase
    Hiroshi Tokumitsu
    Department of Chemistry, Kagawa Medical University, 1750 1 Miki cho, Kita gun, Kagawa 761 0793, Japan
    J Biol Chem 277:15813-8. 2002
    ....
  46. doi Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial
    K H Liesenfeld
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    J Thromb Haemost 9:2168-75. 2011
    ..Dabigatran etexilate (DE) is an orally absorbed prodrug of dabigatran, a thrombin inhibitor that exerts potent anticoagulant and antithrombotic activity...
  47. ncbi An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
    Simon Mantha
    Department of Hematology, Lahey Clinic, Burlington, MA 01805, USA
    Thromb Haemost 108:476-84. 2012
    ..Such an indirect comparison should be used only to generate hypotheses which need to be tested in a dedicated randomised trial comparing the three drugs directly...
  48. ncbi Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation
    Gregory Y H Lip
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
    J Am Coll Cardiol 60:738-46. 2012
    ..This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative efficacy and safety against each other...
  49. pmc Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials
    Vladimir Trkulja
    Department of Pharmacology, Zagreb University School of Medicine, Salata 11, 10000 Zagreb, Croatia
    Croat Med J 51:113-23. 2010
    ..To indirectly compare rivaroxaban and dabigatran for prevention of venous thromboembolism (VTE) after total hip or knee arthroplasty (THA, TKA) based on their pivotal efficacy/safety trials embracing a total of 20618 patients...
  50. ncbi Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
    Jeffrey M Albert
    Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Clin Cancer Res 13:3033-42. 2007
    ..Ionizing radiation induces DNA strand breaks, suggesting that PARP-1 inhibition may sensitize tumor cells to radiation...
  51. ncbi Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator
    T W Kurtz
    Laboratory of Medicine, University of California San Francisco, 185 Berry Street, Suite 290, San Francisco, CA 94107, USA
    Acta Diabetol 42:S9-16. 2005
    ..If the preliminary data are supported by the results of ongoing large-scale clinical studies, telmisartan could have a central role in the prevention and treatment of metabolic syndrome, diabetes and atherosclerosis...
  52. pmc Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors
    Elena V Efimova
    Ludwig Center for Metastasis Research, The University of Chicago, Chicago, Illinois 60637, USA
    Cancer Res 70:6277-82. 2010
    ..PARP inhibition markedly enhanced IRIF persistence and increased breast cancer cell senescence both in vitro and in vivo, arguing for targeting IRIF resolution as a novel therapeutic strategy...
  53. doi Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation
    Kana Tsukuda
    Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Shitsukawa, Tohon, Ehime, Japan
    Hypertension 54:782-7. 2009
    ..Taken together, our findings suggest that even a low dose of telmisartan had a preventive effect on cognitive decline in an Alzheimer disease mouse model, partly because of PPAR-gamma activation...
  54. doi A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Thorac Oncol 5:1630-6. 2010
    ..AZD6244 (ARRY-142886) is a potent, selective MEK inhibitor. This study aimed to evaluate the efficacy and safety of AZD6244 versus pemetrexed as second- or third-line treatment in patients with advanced non-small cell lung cancer (NSCLC)...
  55. doi Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate
    Neil S Roskell
    Neil Roskell, RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, UK
    Thromb Haemost 104:1106-15. 2010
    ..There was no indication of increased intracranial or extracranial haemorrhage with dabigatran etexilate compared to antiplatelet agents...
  56. ncbi Telmisartan: a different angiotensin II receptor blocker protecting a different population?
    M Burnier
    Division of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Int Med Res 37:1662-79. 2009
    ..A class effect for ARBs cannot be assumed. To date, telmisartan is the only ARB that has been shown to reduce cardiovascular risk in at-risk cardiovascular patients...
  57. doi Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial
    Toshio Ogihara
    Osaka University Graduate School of Medicine, Osaka, Japan
    Hypertension 51:393-8. 2008
    ..We disclosed that candesartan-based and amlodipine-based regimens produced no statistical differences in terms of the primary cardiovascular end point, whereas candesartan prevented new-onset diabetes more effectively than amlodipine...
  58. ncbi Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
    Stephen C Benson
    Department of Biological Sciences, California State University, Hayward, USA
    Hypertension 43:993-1002. 2004
    ....
  59. ncbi In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate
    Wolfgang Wienen
    Department of Pulmonary Research, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse, 88397 Biberach, Germany
    Thromb Haemost 98:155-62. 2007
    ..These data suggest that dabigatran is a potent, selective thrombin inhibitor and an orally active anticoagulant as the prodrug, dabigatran etexilate...
  60. doi Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice
    Menno V Huisman
    Department of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, The Netherlands
    Thromb Haemost 107:838-47. 2012
    ..In addition, cut-off values for different coagulation assay results associated with an increased risk of bleeding are given...
  61. doi The use of dabigatran immediately after atrial fibrillation ablation
    Roger A Winkle
    Cardiovascular Medicine and Cardiac Arrhythmias, E Palo Alto, Sequoia Hospital, Redwood City, California, USA
    J Cardiovasc Electrophysiol 23:264-8. 2012
    ..Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events...
  62. pmc Antioxidants prevent ethanol-associated apoptosis in fetal rhombencephalic neurons
    Angeline M Antonio
    Department of Cell Biology, Neurobiology, and Anatomy, Loyola University Stritch School of Medicine, Maywood, IL 60153, USA
    Brain Res 1204:16-23. 2008
    ..e., those cultured in the absence of ethanol. These studies showed that several classes of antioxidants can exert neuroprotection against ethanol-associated apoptosis in fetal rhombencephalic neurons...
  63. ncbi Evaluation of a proposed in vitro test strategy using neuronal and non-neuronal cell systems for detecting neurotoxicity
    J Gartlon
    ECVAM, European Commission Joint Research Centre, via E Fermi 1, Ispra 21020, Italy
    Toxicol In Vitro 20:1569-81. 2006
    ....
  64. pmc Clinical presentation and management of Fasciola hepatica infection: single-center experience
    Muhsin Kaya
    Department of Gastroenterology, Dicle University School of Medicine, Diyarbakir 21280, Turkey
    World J Gastroenterol 17:4899-904. 2011
    ..To identify the characteristic clinical, laboratory and radiological findings and response to treatment in patients with fascioliasis...
  65. ncbi In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models
    Sang Hoon Lee
    Department of Pharmacology, Chiron Corp, Emeryville, California, USA
    Clin Cancer Res 11:3633-41. 2005
    ..To evaluate the therapeutic and biological effects of CHIR-258, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases, in colon cancer models...
  66. doi Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis
    Nadine Nagy
    Institut fur Pharmakologie, Universitatsklinikum Essen, Universitat Duisburg Essen, Hufelandstrasse 55, 45122, Essen, Germany
    Basic Res Cardiol 105:29-38. 2010
    ..Thus, biglycan is a pleiotropic target of telmisartan that might contribute to the anti-atherogenic effects of this AT1-antagonist...
  67. ncbi Taenia solium porcine cysticercosis: viability of cysticerci and persistency of antibodies and cysticercal antigens after treatment with oxfendazole
    C S Sikasunge
    School of Veterinary Medicine, University of Zambia, P O Box 32379, Lusaka, Zambia
    Vet Parasitol 158:57-66. 2008
    ....
  68. ncbi Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery
    Inaki F Troconiz
    Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse 68, 88397 Biberach, Germany
    J Clin Pharmacol 47:371-82. 2007
    ..As a consequence, the rate of absorption is reduced and interindividual variability in drug exposure increased. On the following days, the disposition in plasma of BIBR 953 ZW is less variable...
  69. ncbi Modulation of Cl- secretion by benzimidazolones. I. Direct activation of a Ca(2+)-dependent K+ channel
    D C Devor
    Department of Cell Biology and Physiology, University of Pittsburgh, Pennsylvania 15261, USA
    Am J Physiol 271:L775-84. 1996
    ..1-EBIO is the first pharmacological opener of this important class of epithelial K+ channels to be identified...
  70. ncbi Telmisartan, a partial agonist of peroxisome proliferator-activated receptor gamma, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia
    Tamami Haraguchi
    Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814 0180, Japan
    Brain Res 1353:125-32. 2010
    ..Telmisartan, which has the unique character of having both ARB and PPARgamma agonistic effect, will be useful for preventing memory impairment after cerebrovascular disease...
  71. doi Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison
    Y K Loke
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK
    J Clin Pharm Ther 36:111-24. 2011
    ..Dabigatran and rivaroxaban are new oral anticoagulants for thromboprophylaxis after elective orthopaedic surgery. We aimed to systematically compare their relative benefits and harms through meta-analysis, and adjusted indirect comparison...
  72. ncbi Dual repressive effect of angiotensin II-type 1 receptor blocker telmisartan on angiotensin II-induced and estradiol-induced uterine leiomyoma cell proliferation
    Aki Isobe
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Hum Reprod 23:440-6. 2008
    ..Elevated blood pressure has an independent, positive association with risk for clinically detected uterine leiomyoma. Angiotensin II (Ang II) is a key biological peptide in the renin-angiotensin system that regulates blood pressure...
  73. doi Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration
    Begoña Villar-Cheda
    Laboratory of Neuroanatomy and Experimental Neurology, Department of Morphological Sciences, Faculty of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
    Neurobiol Aging 33:204.e1-11. 2012
    ..Furthermore, the results suggest that manipulation of the brain angiotensin system may constitute an effective neuroprotective strategy against aging-related risk of dopaminergic degeneration...
  74. pmc Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca2+ in T lymphocytes
    Peter Tamas
    Division of Cell Biology and Immunology, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom
    J Exp Med 203:1665-70. 2006
    ..Moreover, AMPK does not just react to cellular energy depletion but also anticipates it...
  75. ncbi AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma
    Hung Huynh
    Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore 169610
    Mol Cancer Ther 6:2468-76. 2007
    ..Our study provides a strong rationale for clinical investigation of combination therapy with the mitogen-activated protein/ERK kinase 1/2 inhibitor AZD6244 and doxorubicin in patients with HCC...
  76. ncbi The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses
    Peter Trenkwalder
    Department of Internal Medicine, Starnberg Hospital, Ludwig Maximilian University Munich, Starnberg, Germany
    J Hypertens Suppl 24:S107-14. 2006
    ..Results in other subgroups were generally consistent with those in the entire SCOPE study population. In patients with slightly low cognitive function at baseline, the MMSE score declined less in the candesartan group...
  77. ncbi Structure-based design of novel potent nonpeptide thrombin inhibitors
    Norbert H Hauel
    Boehringer Ingelheim Pharma KG, Research Division, Birkendorfer Strasse 65, D 88397 Biberach Riss, Germany
    J Med Chem 45:1757-66. 2002
    ..This zwitterionic molecule was converted into the double-prodrug 31 (BIBR 1048), which showed strong oral activity in different animal species. On the basis of these results, 31 was chosen for clinical development...
  78. pmc Angiotensin II AT1 receptor blockade ameliorates brain inflammation
    Julius Benicky
    Section on Pharmacology, Division of Intramural Research Programs, Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 36:857-70. 2011
    ..Our results indicate that these compounds may offer a novel and safe therapeutic approach for the treatment of brain disorders...
  79. ncbi The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques
    Christopher J French
    Department of Medicine, Cardiovascular Research Institute, University of Vermont, Burlington, VT, USA
    J Cardiovasc Pharmacol 58:143-8. 2011
    ..Accordingly, the suppression of PAI-1 expression by AZL-M may attenuate the evolution of atherosclerotic plaques vulnerable to rupture...
  80. doi Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker
    Takashi Kajiya
    Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduate School of Medicine, Kagoshima University, Kagoshima, Japan
    J Hypertens 29:2476-83. 2011
    ..Although azilsartan is considered to be an unusually potent angiotensin II type 1 (AT1) receptor antagonist, little is known about the potential pleiotropic effects of this molecule...
  81. pmc Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records
    Yayoi Nishida
    Division of Genomic Epidemiology and Clinical Trials, Advanced Medical Research Center, Nihon University School of Medicine, 30 1 Oyaguchi Kamimachi, Itabashi ku, Tokyo 173 8610, Japan
    Cardiovasc Diabetol 9:38. 2010
    ..Our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of ARB monotherapy with candesartan...
  82. doi Estimation of the cost of large-scale school deworming programmes with benzimidazoles
    A Montresor
    Department of Control of Neglected Tropical Diseases, World Health Organization, 20 Avenue Appia, 1211 Geneva, Switzerland
    Trans R Soc Trop Med Hyg 104:129-32. 2010
    ....
  83. pmc Renal protection in diabetes: lessons from ONTARGET
    Eberhard Ritz
    Universitat Erlangen, Medizinische Klinik IV, Erlangen, Germany
    Cardiovasc Diabetol 9:60. 2010
    ....
  84. doi Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models
    Keiji Kusumoto
    Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Osaka, Japan
    Eur J Pharmacol 669:84-93. 2011
    ..These results suggest that azilsartan medoxomil is a potent angiotensin II receptor blocker that has an attractive pharmacological profile as an antihypertensive agent...
  85. pmc Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness
    Paul P Szotek
    Pediatric Surgical Research Laboratories, Department of Surgery, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 103:11154-9. 2006
    ..In the future, individualized therapy must incorporate analysis of the stem cell-like subpopulation of ovarian cancer cells when designing therapeutic strategies for ovarian cancer patients...
  86. ncbi Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program
    Akshay S Desai
    Department of Cardiology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1959-66. 2007
    ..We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients...
  87. doi The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer
    Udai Banerji
    Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    Clin Cancer Res 16:1613-23. 2010
    ..In part B, the aim was to compare the pharmacokinetic profile of the new Hyd-Sulfate capsule with the initial AZD6244 free-base suspension and further characterize the pharmacodynamic profile and efficacy of the new formulation...
  88. ncbi Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction
    Thomas E Jensen
    Department of Human Physiology, Copenhagen Muscle Research Centre, Institute of Exercise and Sport Sciences, University of Copenhagen, Copenhagen, Denmark
    Am J Physiol Endocrinol Metab 292:E1308-17. 2007
    ....
  89. doi Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation
    Michael D Ezekowitz
    Lankenau Institute for Medical Research, 100 Lancaster Ave, Suite G36, Wynnewood, PA 19096, USA
    Circulation 122:2246-53. 2010
    ..The comparison of anticoagulants dabigatran and warfarin might be most equitable in vitamin K antagonist (VKA)-naive patients...
  90. pmc Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels
    C Hougaard
    Neurosearch A S, Pederstrupvej 93, Ballerup, Denmark
    Br J Pharmacol 151:655-65. 2007
    ..This paper demonstrates, for the first time, subtype-selective positive modulation of SK channels...
  91. ncbi Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia
    Yukiko Kasahara
    Department of Cerebrovascular Disease, National Cardiovascular Center, Osaka, Japan
    Brain Res 1340:70-80. 2010
    ....
  92. pmc BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines
    Rebecca Leboeuf
    Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Endocrinol Metab 93:2194-201. 2008
    ..Although the signal output common to these oncoproteins is ERK, a recent report showed that only BRAF mutations consistently predicted responsiveness to MAPK kinase (MEK) inhibitors...
  93. ncbi Formation of cellular projections in neural progenitor cells depends on SK3 channel activity
    Stefan Liebau
    Department of Anatomy and Cell Biology, University of Ulm, Ulm, Germany
    J Neurochem 101:1338-1350. 2007
    ..Both effects could be prevented by the pre-incubation of NPCs with ScTX. Our study gives first evidence that the formation and prolongation of filopodia in NPCs is, at least in part, effectively induced and regulated by SK3 channels...
  94. pmc Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs
    Kwang Kon Koh
    Vascular Medicine and Atherosclerosis Unit, Cardiology, Gil Medical Center, Gachon University, Incheon, Republic of Korea
    Int J Cardiol 140:73-81. 2010
    ..This is not explained by changes in blood pressure alone. We hypothesized that distinct vascular and metabolic effects of anti-hypertensive drugs may explain these differential effects...
  95. ncbi Long-term regulation of ENaC expression in kidney by angiotensin II
    Kathleen T Beutler
    Laboratory of Kidney and Electrolyte Metabolism, NHLBI, National Institutes of Health, Bethesda, MD 20892 1603, USA
    Hypertension 41:1143-50. 2003
    ..The results support the view that the angiotensin II receptor regulates ENaC abundance, consistent with a role for angiotensin II in regulation of collecting duct function...
  96. pmc Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
    Alex A Adjei
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Clin Oncol 26:2139-46. 2008
    ..To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer...
  97. ncbi Spontaneous changes in mitochondrial membrane potential in cultured neurons
    J F Buckman
    Department of Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261
    J Neurosci 21:5054-65. 2001
    ..We hypothesize that these DeltaPsi(m) fluctuations are dependent on the proper functioning of the mitochondria and reflect mitochondria alternating between the active and inactive states of oxidative phosphorylation...
  98. ncbi Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
    Christopher B Granger
    Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 362:772-6. 2003
    ..We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor...
  99. ncbi Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies
    David H G Smith
    Blood Press Monit 8:111-7. 2003
    ....
  100. ncbi Combined human and porcine mass chemotherapy for the control of T. solium
    H H Garcia
    Department of Microbiology, Universidad Peruana Cayetano Heredia, San Martin de Porras, Lima, Peru
    Am J Trop Med Hyg 74:850-5. 2006
    ..Mass chemotherapy was effective in decreasing infection pressure in this hyperendemic area. However, the magnitude of the effect was small and did not attain the goal of eliminating transmission...
  101. pmc Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
    C E Mogensen
    Department of Medicine, M, Kommunehospitalet, University Hospital, DK 8000 Aarhus C, Denmark
    BMJ 321:1440-4. 2000
    ..To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes...

Research Grants114 found, 100 shown here

  1. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2006
    ..Hypertension candidate genes will then be isolated using cDNA screening techniques to identify genes expressed in the brain, adrenal gland, or kidney that map within this chromosome region. ..
  2. Oxidative Stress in Oral Streptococci
    Robert E Marquis; Fiscal Year: 2010
    ..Aim 3 is focused on translational research with investigation of small molecules, such as zinc cations, benzimidazoles or other sulfhydryl-reacting agents, such as allicin, chelators, fluoride and other halogens, transition metal ..
  3. ANTIFUNGAL RESPONSE--MDR INDUCTION
    Thomas Edlind; Fiscal Year: 2001
    ..indicate that MDR induction is the most likely explanation for the intrinsic resistance of Candida species to benzimidazoles and for the antagonistic activity between compounds that induce MDR (albendazole and sulfadiazine) and ..
  4. ANTIFUNGAL RESPONSE--MDR INDUCTION
    Thomas Edlind; Fiscal Year: 1999
    ..indicate that MDR induction is the most likely explanation for the intrinsic resistance of Candida species to benzimidazoles and for the antagonistic activity between compounds that induce MDR (albendazole and sulfadiazine) and ..
  5. ANTIFUNGAL RESPONSE--MDR INDUCTION
    Thomas Edlind; Fiscal Year: 2000
    ..indicate that MDR induction is the most likely explanation for the intrinsic resistance of Candida species to benzimidazoles and for the antagonistic activity between compounds that induce MDR (albendazole and sulfadiazine) and ..
  6. ANTIFUNGAL RESPONSE--MDR INDUCTION
    Thomas Edlind; Fiscal Year: 2002
    ..indicate that MDR induction is the most likely explanation for the intrinsic resistance of Candida species to benzimidazoles and for the antagonistic activity between compounds that induce MDR (albendazole and sulfadiazine) and ..
  7. DISCRIMINATION BETWEEN VIABLE & DEAD ENCEPHALITOZOON CUNICULI (MICROSPORIDIA)
    Linda Green; Fiscal Year: 2000
    ..were assayed for antimicrosporidial activity in an in vitro culture system and included a) approximately 20 benzimidazoles, b) approximately 25 tubulin-binding deazapteridines and deazapurines, c) 14 protease inhibitors, d) 10 ..
  8. DICATIONIC DRUGS--TREATMENT FOR AIDS-RELATED INFECTIONS
    Richard Tidwell; Fiscal Year: 1999
    ..and pyrimidine ring systems as spacers between the cationic centers, while the UNC-CH group will focus on benzimidazoles, carbazoles and alpha, omega, dioxyalkanes. The choice of these spacing units is based on our previous studies...
  9. Novel Antimicrobials Targeting Cell Division
    Iwao Ojima; Fiscal Year: 2010
    ..tubulin/microtubules and has hypothesized that a certain class of taxanes (microtubule-stabilizer) and benzimidazoles (tubulin polymerization inhibitors) should inhibit the depolymerization or polymerization of FtsZ from ..
  10. Novel Antimicrobials Targeting Cell Division
    Iwao Ojima; Fiscal Year: 2011
    ..tubulin/microtubules and has hypothesized that a certain class of taxanes (microtubule-stabilizer) and benzimidazoles (tubulin polymerization inhibitors) should inhibit the depolymerization or polymerization of FtsZ from ..
  11. Novel Antimicrobials Targeting Cell Division
    Iwao Ojima; Fiscal Year: 2009
    ..tubulin/microtubules and has hypothesized that a certain class of taxanes (microtubule-stabilizer) and benzimidazoles (tubulin polymerization inhibitors) should inhibit the depolymerization or polymerization of FtsZ from ..
  12. Enantioselective Total Synthesis of Marcfortine B via SmI2-mediated C-C Bond Form
    TIMOTHY KUM BENG; Fiscal Year: 2012
    ..Macrocyclic lactones, benzimidazoles, and imidazothiazoles are at present being used for the eradication of gastrointestinal nematodes in ..
  13. Synthesis and Biology of Bengazole Analogs
    Peter Wipf; Fiscal Year: 2002
    ..has suffered major setbacks, since resistance of nematodes to the anthelminthic drugs of general use such as benzimidazoles levamizole and praziquantel has emerged...
  14. Synthesis and Biology of Bengazole Analogs
    Peter Wipf; Fiscal Year: 2001
    ..has suffered major setbacks, since resistance of nematodes to the anthelminthic drugs of general use such as benzimidazoles levamizole and praziquantel has emerged...
  15. Synthesis and Biology of Bengazole Analogs
    Peter Wipf; Fiscal Year: 2003
    ..has suffered major setbacks, since resistance of nematodes to the anthelminthic drugs of general use such as benzimidazoles levamizole and praziquantel has emerged...
  16. P CARINII MICROTUBULES--GENETICS & BENZIMIDAZOLE TARGET
    Thomas Edlind; Fiscal Year: 1992
    ..Consistent with their importance, microtubules are targets for a wide variety of drugs and toxins. The benzimidazoles are notable, however, for their low toxicity to mammalian cells but high activity against helminth and fungal ..
  17. STRUCTURAL AND GENETIC ASPECTS OF TUBULIN INTERACTIONS
    LYNWOOD YARBROUGH; Fiscal Year: 1990
    ..in terms of its assembly, stability, and susceptibility to antimitotic agents such as colchicine and the benzimidazoles. 3...
  18. HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING
    Michael McVoy; Fiscal Year: 2004
    ..Recent findings in GPCMV and HCMV suggest that the benzimidazoles induce a premature cleavage to produce truncated genomes...
  19. HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING
    Michael McVoy; Fiscal Year: 2005
    ..Recent findings in GPCMV and HCMV suggest that the benzimidazoles induce a premature cleavage to produce truncated genomes...
  20. HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING
    Michael McVoy; Fiscal Year: 2001
    ..Recent findings in GPCMV and HCMV suggest that the benzimidazoles induce a premature cleavage to produce truncated genomes...
  21. HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING
    Michael McVoy; Fiscal Year: 2003
    ..Recent findings in GPCMV and HCMV suggest that the benzimidazoles induce a premature cleavage to produce truncated genomes...
  22. HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING
    Michael McVoy; Fiscal Year: 2002
    ..Recent findings in GPCMV and HCMV suggest that the benzimidazoles induce a premature cleavage to produce truncated genomes...
  23. ANALYSIS OF AH RECEPTOR LIGAND BINDING SPECIFICITY
    Michael Denison; Fiscal Year: 2001
    ..The mechanism by which benzimidazoles, selected pesticides and other chemicals activate the AhR in a "ligand-independent manner" and the ability of ..
  24. ANALYSIS OF AH RECEPTOR LIGAND BINDING SPECIFICITY
    Michael Denison; Fiscal Year: 2002
    ..The mechanism by which benzimidazoles, selected pesticides and other chemicals activate the AhR in a "ligand-independent manner" and the ability of ..
  25. ANALYSIS OF AH RECEPTOR LIGAND BINDING SPECIFICITY
    Michael Denison; Fiscal Year: 2000
    ..The mechanism by which benzimidazoles, selected pesticides and other chemicals activate the AhR in a "ligand-independent manner" and the ability of ..
  26. NOVEL SULTAMS AND LACTAMS AS POTENTIAL ANTICONVULSANTS
    RUDOLPH ABRAMOVITCH; Fiscal Year: 1980
    ..1,2-benzo-1,2-diazepines, and 1,2-benzazepinones, as well as to benzothiazoles, benzoxazoles, benzimidazoles, and (3H)-indolones to yield the corresponding benz-fused seven-membered heterocycles...
  27. HCMV EVALUATION, BIOCHEMISTRY, AND VIRAL GENETICS
    JOHN DRACH; Fiscal Year: 1999
    ..We shall evaluate for antiviral activity and cytotoxicity new series of nucleoside analogs (benzimidazoles and indoles) and related heterocyclics prepared in the laboratory of Dr...
  28. Oxidative Stress in Oral Streptococci
    Robert Marquis; Fiscal Year: 2009
    ..Aim 3 is focused on translational research with investigation of small molecules, such as zinc cations, benzimidazoles or other sulfhydryl-reacting agents, such as allicin, chelators, fluoride and other halogens, transition metal ..
  29. Oxidative Stress in Oral Streptococci
    Robert Marquis; Fiscal Year: 2007
    ..Aim 3 is focused on translational research with investigation of small molecules, such as zinc cations, benzimidazoles or other sulfhydryl-reacting agents, such as allicin, chelators, fluoride and other halogens, transition metal ..
  30. DINITROANILINE HERBICIDE METABOLISM & TOXICOLOGY
    JUDD NELSON; Fiscal Year: 1980
    ..to synthesize prospective metabolites of dinitroaniline herbicides, particularly the polar derivatives such as benzimidazoles and their N-oxides, dihydroxy-benzimidazolines, etc., for use as reference standards...
  31. Oxidative Stress in Oral Streptococci
    Robert Marquis; Fiscal Year: 2006
    ..Aim 3 is focused on translational research with investigation of small molecules, such as zinc cations, benzimidazoles or other sulfhydryl-reacting agents, such as allicin, chelators, fluoride and other halogens, transition metal ..
  32. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2003
    ....
  33. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2010
    ..Detailed understanding of the genetic mechanisms of resistance will improve the design of suitable new drug structures and antiviral targets. ..
  34. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  35. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2002
    ....
  36. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2005
    ....
  37. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2004
    ....
  38. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 1999
    ..W. Lawrence Drew (UCSF) and from Dr. Alejo Erice (University of Minnesota). ..
  39. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2001
    ....
  40. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2009
    ..Detailed understanding of the genetic mechanisms of resistance will improve the design of suitable new drug structures and antiviral targets. ..
  41. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  42. Contingency Management for Initiating Smoking Abstinence
    WILLIAM BARRY WHITE; Fiscal Year: 2010
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
  43. Contingency Management for Initiating Smoking Abstinence
    William White; Fiscal Year: 2009
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
  44. Contingency Management for Initiating Smoking Abstinence
    William White; Fiscal Year: 2008
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
  45. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2003
    ..Under this alternative hypothesis, the results of the cDNA microarray analysis will be used to identify potential downstream target genes whose expression is altered by the primary genetic defect on chromosome 1. ..
  46. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 1999
    ....
  47. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2000
    ..Under this alternative hypothesis, the results of the cDNA microarray analysis will be used to identify potential downstream target genes whose expression is altered by the primary genetic defect on chromosome 1. ..
  48. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2002
    ..Under this alternative hypothesis, the results of the cDNA microarray analysis will be used to identify potential downstream target genes whose expression is altered by the primary genetic defect on chromosome 1. ..
  49. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2009
    ..This project is designed to investigate genetic factors that influence the development of the metabolic syndrome and ultimately help identify new targets for prevention and treatment of diabetes and cardiovascular disease. ..
  50. Oxidative Stress and Genetics of Prehypertension
    Shawna Nesbitt; Fiscal Year: 2004
    ..abstract_text> ..
  51. Oxidative Stress and Genetics of Prehypertension
    Shawna Nesbitt; Fiscal Year: 2003
    ..abstract_text> ..
  52. Natriuretic Mechanisms Uderlying Spontaneous Hypertension
    Shetal Padia; Fiscal Year: 2008
    ..Identification of these defects are essential to our understanding of the pathogenesis of essential hypertension in humans. ..
  53. Oxidative Stress and Genetics of Prehypertension
    Shawna Nesbitt; Fiscal Year: 2002
    ..abstract_text> ..
  54. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2008
    ..This project is designed to investigate genetic factors that influence the development of the metabolic syndrome and ultimately help identify new targets for prevention and treatment of diabetes and cardiovascular disease. ..
  55. CTGF-interacting proteins in scleroderma lung fibrosis
    GALINA BOGATKEVICH; Fiscal Year: 2008
    ..The identified protein(s) might serve then as potential target(s) in the treatment of scleroderma pulmonary fibrosis for which no proven, effective therapy currently exists. ..
  56. NICOTINIC RECEPTORS IN MAMMALIAN INTRACARDIAC NEURONS
    Javier Cuevas; Fiscal Year: 2000
    ..An understanding of the properties and physiological role of the receptors is necessary to comprehend neural control of the heart. ..
  57. WHY DO METABOLIC RISK FACTORS CLUSTER WITH HYPERTENSION?
    Theodore Kurtz; Fiscal Year: 2002
    ....
  58. Synthesis and Testing of Rigid CDK5 inhibitors
    Patrick Flaherty; Fiscal Year: 2008
    ..We hope that by preventing NFT formation, we can help America preserve its memory and recognize its future. [unreadable] [unreadable] [unreadable]..
  59. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 1999
    ..Finally, they will distribute these strains to other investigators also interested in studying pathophysiologic mechanisms whereby selected chromosome regions may influence cardiovascular function and BP. ..
  60. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2001
    ..Under this alternative hypothesis, the results of the cDNA microarray analysis will be used to identify potential downstream target genes whose expression is altered by the primary genetic defect on chromosome 1. ..
  61. Altered Accumbens Signaling Following Ethanol Exposure
    FREDERIC HOPF; Fiscal Year: 2007
    ..Altered spike firing and dopamine signaling in the NAcb could significantly influence the behavioral contribution of the NAcb, and in this way facilitate the onset of relapse. ..
  62. Altered Accumbens Signaling Following Ethanol Exposure
    FREDERIC HOPF; Fiscal Year: 2009
    ..Altered spike firing and dopamine signaling in the NAcb could significantly influence the behavioral contribution of the NAcb, and in this way facilitate the onset of relapse. ..
  63. Sir2 regulation and chemical modulation
    Anthony Sauve; Fiscal Year: 2008
    ..abstract_text> ..
  64. Sir2 regulation and chemical modulation
    Anthony Sauve; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  65. Sir2 regulation and chemical modulation
    Anthony Sauve; Fiscal Year: 2009
    ..abstract_text> ..
  66. Altered Accumbens Signaling Following Ethanol Exposure
    FREDERIC HOPF; Fiscal Year: 2008
    ..Altered spike firing and dopamine signaling in the NAcb could significantly influence the behavioral contribution of the NAcb, and in this way facilitate the onset of relapse. ..
  67. Sir2 regulation and chemical modulation
    Anthony A Sauve; Fiscal Year: 2010
    ..abstract_text> ..
  68. Sir2 regulation and chemical modulation
    Anthony Sauve; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  69. Sir2 regulation and chemical modulation
    Anthony A Sauve; Fiscal Year: 2010
    ..abstract_text> ..
  70. Altered Accumbens Signaling Following Ethanol Exposure
    FREDERIC HOPF; Fiscal Year: 2006
    ..Altered spike firing and dopamine signaling in the NAcb could significantly influence the behavioral contribution of the NAcb, and in this way facilitate the onset of relapse. ..
  71. Altered Accumbens Signaling Following Ethanol Exposure
    FREDERIC WOODWARD HOPF; Fiscal Year: 2010
    ..Altered spike firing and dopamine signaling in the NAcb could significantly influence the behavioral contribution of the NAcb, and in this way facilitate the onset of relapse. ..
  72. Intrathecal Opioid-Induced Pruritus
    Mei Chuan Ko; Fiscal Year: 2002
    ..These studies would provide a systematic understanding of the pharmacology of intrathecal morphine-induced pruritus in primates and establish the basis for identifying potential therapeutically effective antipruritics. ..
  73. NITRIC OXIDE SYNTHASE IN THE JUXTAGLOMERULAR APPARATUS
    CHRISTOPHER WILCOX; Fiscal Year: 2001
    ..abstract_text> ..
  74. Nephrology and Hypertension Training Grant
    CHRISTOPHER WILCOX; Fiscal Year: 2008
    ..The aim is to train physicians and post doctoral scientists, for a career in academic nephrology and hypertension. ..
  75. NITRIC OXIDE SYNTHASE IN THE JUXTAGLOMERULAR APPARATUS
    CHRISTOPHER WILCOX; Fiscal Year: 2009
    ..abstract_text> ..
  76. Chondroleukin and Articular Cartilage
    A Reddi; Fiscal Year: 2002
    ..Aim 2A. To identify the cognate receptors of lL-17B in articular chondrocytes. Aim 2B. To examine the hypothesis that the novel lL-17 receptor-like molecule (IL-1 7RL) is a functional receptor in articular cartilage. ..
  77. REGULATION OF RENAL FUNCTION AND BP BY THROMBOXANE
    CHRISTOPHER WILCOX; Fiscal Year: 2000
    ....
  78. DEVELOPMENT OF A LIVE ATTENUATED HSV-2 VACCINE
    Mark Prichard; Fiscal Year: 2002
    ..In addition further in vitro characterization will enable high quality clinical trial material to be produced for IND enabling primate studies and early Phase I human trials. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  79. HIV ASSOCIATED NEPHROPATHY IN DRUG ADDICTS
    Pravin Singhal; Fiscal Year: 2005
    ..2. Oxidative stress modulated by drugs accelerates the progression of renal injury in a mouse model of HIVAN. 3. Drugs modulation of the renin-angiotensin system contributes to the progression of renal lesions in mice with HIVAN. ..
  80. NITRIC OXIDE SYNTHASE IN THE JUXTAGLOMERULAR APPARATUS
    CHRISTOPHER WILCOX; Fiscal Year: 2006
    ..abstract_text> ..
  81. A pharmacogenetic and pharmacodynamic study of erlotinib
    CHARLES RUDIN; Fiscal Year: 2004
    ..Defining the basis of this toxicity could also promote the development of EGFR-directed agents that may avoid such toxicity or that may be effective in a broader spectrum of cancer patients. ..
  82. Chondroleukin and Articular Cartilage
    A Reddi; Fiscal Year: 2003
    ..Aim 2A. To identify the cognate receptors of lL-17B in articular chondrocytes. Aim 2B. To examine the hypothesis that the novel lL-17 receptor-like molecule (IL-1 7RL) is a functional receptor in articular cartilage. ..
  83. OXIDATIVE STRESS IN THE KIDNEY IN HYPERTENSION
    CHRISTOPHER WILCOX; Fiscal Year: 2007
    ..The goal of this work is to provide a basis for better understanding of the role of ROS in hypertension and its consequences and thereby providing a rational basis for new forms of prevention or treatment. ..
  84. Proteosome Inhibition Therapy for Hematologic Malignancy
    Terzah Horton; Fiscal Year: 2007
    ..The phase I studies will be used to further refine correlative biology studies for the proposed phase 2 clinical trials that will examine the effectiveness of bortezomib as a chemosensitizing agent in relapsed ALL and HL. ..